Effect of imatinib in bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation

• Project/Area Number: 23790901
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Respiratory organ internal medicine
• Research Institution: Kanazawa University
• Principal Investigator: WASEDA Yuko 金沢大学, 医学系, 助教 (80536037)
• Project Period (FY): 2011 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000); Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000); Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
• Keywords: 閉塞性細気管支炎 / 同種造血幹細胞移植 / 肺移植

Research Abstract

In the mouse lung transplantation model, BO was significantly controlled when we used the c-kit knockout model as donor. We had the possibility to be able to reduce BO, which is the biggest complications after the lung transplantation, by controlling c-kit of the donor. Therefore, We thought about the possibility that we could decrease BO with imatinib.